[A case report of renal cell carcinoma developing in a sole functioning kidney].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to K Takada.
Explore the source record for details and available documents.
Sera and peripheral blood lymphocytes in 40 clinical cases of adult T-cell leukemia (ATL) and 66 cases of mature T-cell malignancies in Hokkaido district, the most northern part of Japan, were examined for the infection with ATL virus (ATLV). All of the 40 ATL patients (100%) had antibodies to ATLV-associated antigen (ATLA) and 13 (19.7%) of the 66 patients with mature T-cell malignancies other than ATL were also positive for anti-ATLA. When the peripheral ATL lymphocytes were assessed after short time cultivation, both ATLA antigen and C type virus particles were detectable. In contrast to the high prevalence of ATLV antibodies in these patients, the positivity in 30,000 control individuals in this district was 0.73%. It was calculated that 8 patients of a 40,000 seropositive population are diagnosed annually as ATL in this particular northern part of Japan.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The hemodialysability of bredinin, a new immunosuppressive drug, was investigated in five patients on longterm hemodialysis. Blood samples were collected periodically during and inter-dialysis and measured by high-performance liquid chromatography (HPLC) for bredinin. The half-life (t 1/2) of the elimination phase was 4.8 h in our patients during hemodialysis, a 97% reduction of the 155 h t 1/2 reported in uremic patients. The fraction of drug in the body which is removed by dialysis (f) calculated averaged 0.43. A mean of 43% of the drug in the body was removed during 4-hour hemodialysis. Because of the reduction in elimination t 1/2 and the significant drug removal during dialysis we conclude that bredinin is dialyzable.
Explore the source record for details and available documents.